Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
NCT07451652Phase 2Recruiting
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Started Mar 2026; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07451652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451652.